As filed with the Securities and Exchange Commission on June 14, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
TSCAN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 82-5282075 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
830 Winter Street Waltham, Massachusetts | 02451 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
TSCAN THERAPEUTICS, INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN
(Full title of the plan)
Gavin MacBeath
Chief Executive Officer
TScan Therapeutics, Inc.
830 Winter Street
Waltham, Massachusetts 02451
(Name and address of agent for service)
(857) 399-9500
(Telephone number, including area code, of agent for service)
Copies to:
Mitchell S. Bloom, Esq.
William D. Collins, Esq.
Finnbarr Murphy, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 registers 2,000,000 additional shares of the Registrant’s common stock, $0.0001 par value per share (“Common Stock”), under the TScan Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”). The additional shares are of the same class as other securities relating to the 2021 Plan for which the Registrant’s registration statements filed on Form S-8 with the Securities and Exchange Commission on July 16, 2021 (Registration No. 333-257941), March 9, 2022 (Registration No. 333-263380), March 8, 2023 (Registration No. 333-270343), June 16, 2023 (Registration No. 333-272733) and March 6, 2024 (Registration No. 333-277695) are effective. The information contained in the Registrant’s registration statements on Form S-8 (Registration No. 333-257941, No. 333-263380, No. 333-270343, No. 333-272733 and No. 333-277695) is hereby incorporated by reference pursuant to General Instruction E, except with respect to Item 8. Exhibits thereof.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
| * | Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on June 14, 2024.
| TScan Therapeutics, Inc. | ||
| By: | /s/ Gavin MacBeath | |
| Gavin MacBeath, Ph.D. | ||
Chief Executive Officer (Principal Executive Officer) | ||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gavin MacBeath and Jason A. Amello, and each of them, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for such person in such person’s, place and stead, in any and all capacities, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 of TScan Therapeutics, Inc., and any or all amendments (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Gavin MacBeath Gavin MacBeath | Chief Executive Officer and Director (Principal Executive Officer) | June 14, 2024 | ||
/s/ Jason A. Amello Jason A. Amello | Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer) | June 14, 2024 | ||
/s/ Stephen Biggar Stephen Biggar, M.D., Ph.D. | Director | June 14, 2024 | ||
/s/Barbara Klencke, M.D. Barbara Klencke, M.D. | Director | June 14, 2024 | ||
/s/ Garry Nicholson Garry Nicholson | Director | June 14, 2024 | ||
/s/ Gabriela Gruia | Director | June 14, 2024 | ||
| Gabriela Gruia, M.D. | ||||
/s/ Katina Dorton Katina Dorton, J.D., M.B.A. | Director | June 14, 2024 | ||
/s/ R. Keith Woods | Director | June 14, 2024 | ||
| R. Keith Woods | ||||
